Pharmaceutical

Global stock market crash likely to delay biotech IPOs

Biotech IPOs were up six-fold in Q1 2024 from the previous quarter, but the current global stock market crash means a sustained rebound is in jeopardy.

Aug 7, 2024 - 04:00
Global stock market crash likely to delay biotech IPOs
Biotech IPOs were up six-fold in Q1 2024 from the previous quarter, but the current global stock market crash means a sustained rebound is in jeopardy.
Read the original article

Tags:

Previous Article

Developing high-potent APIs: The necessary steps to follow

Next Article

How SaaS platforms are breaking the mold for clinical trials

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Study on Amgen’s ‘bispecific’ immunotherapy could lead to approval in small cell lung cancer

STAT+: Study on Amgen’s ‘bispecific’ immunotherapy coul...

Oct 20, 2023

Biohaven licenses Hangzhou Highlightll’s BHV-8000 to treat brain disorders

Biohaven licenses Hangzhou Highlightll’s BHV-8000 to tr...

Mar 23, 2023

Simtra BioPharma to invest more than $250m in US facility

Simtra BioPharma to invest more than $250m in US facility

Mar 1, 2024